SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat

Article citations


Mangano, D.T., Miao, Y., Vuylsteke, A., et al. (2007) Mortality Associated with Aprotinin during 5 Years Following Coronary Artery Bypass Graft Surgery. JAMA, 297, 471-479.

has been cited by the following article:

  • TITLE: Redo Cardiac Surgery: Bleeding Control

    AUTHORS: A. Seghrouchni, M. Bamous, Y. Moutakiallah, F. Nya, N. Atmani, A. Abdou, M. Belkhadir, S. Bellouize, A. Abetti, R. Mounir, A. Moujahid, A. G. Hatim, M. Drissi, Y. El Bekkali, A. Boulahya, M. Ait. Houssa

    KEYWORDS: Cardiac Surgery, Aprotinin, Tranexamic Acid, Cardiopulmonary Bypass

    JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.7 No.9, September 25, 2017

    ABSTRACT: Redo cardiac surgery increasesmortality and morbidity. The aim of this study was to determine if aprotinin was superior to tranexamic acid concerning control bleeding loss after redo valve surgery. A retrospective study was conducted from January 1994 until December 2014. 221 patients underwent redo cardiac valve surgery and separated into two groups: aprotinin group (n=85) and tranexamic acid group (n=136). Univariate tests were applied for data analysis. A total of 221 patients were enrolled in this study. This cohort was separated into two groups: aprotinin group (n=85) and tranexamic acid group (n=136). Euroscore in tranexamic acid group was higher: 5.96 ± 3.04 vs.5.17 ± 2.83 in aprotinin group(p=0.055). There was no statistical difference in postoperative mortality between the two groups (p= 0.153). No statistical differences were reported concerning: total blood loss (p= 0.51), red blood cells transfusion (p= 0.215), reexploration for bleeding (p= 0.537) and postoperative renal failure (p= 0.79). There were statistical differences concerning mechanical ventilation time, which is longer in tranexamic acid group (p= 0.008) and the use of inotropic drug support, which is more frequent in the tranexamic acid group (p= 0.001). Our results demonstrated that tranexamic acid and aprotinin reduce transfusion requirement and blood loss. Due to financial reason, we chose tranexamic acid in preventing blood loss in redo valve surgery.